CoChat

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies

Open access
Ishida, Takashi, Utsunomiya, Atae, Jo, Tatsuro, Yamamoto, Kazuhito, Kato, Koji, Yoshida, Shinichiro, Takemoto, Shigeki, Suzushima, Hitoshi, Kobayashi, Yukio, Imaizumi, Yoshitaka, Yoshimura, Kenichi, Kawamura, Kouichi, Takahashi, Takeshi, Tobinai, Kensei, Ueda, Ryuzo · 2017 · Cancer Science
Cited by 71

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The present study sought to elucidate the prognosis of adult T‐cell leukemia–lymphoma (ATL) patients receiving mogamulizumab, a defucosylated anti‐CCR 4 monoclonal antibody. Progression‐free survival (PFS) and overall survival (OS) of ATL patients enrolled in two studies are herein updated, namely NCT 00355472 (phase I study of mogamulizumab in relapsed patients with ATL and peripheral T‐cell lymphoma) and NCT 00920790 (phase II study for relapsed ATL). Of 13 patients with relapsed aggressive ATL in the phase I study, four (31%) survived >3 years. For 26 relapsed patients with aggressive ATL in the phase II study, median PFS was 5.2 months and 1‐year PFS was 26%, whereas median OS was 14.4 months, and 3‐year OS was 23%. For patients without a rash or who developed a grade 1 rash only, median PFS was 0.8 months, and 1‐year PFS was zero, with a median OS of 6.0 months, and 3‐year OS of 8%. In contrast, for patients who developed a rash ≥grade 2, median PFS was 11.7 months, and 1‐year PFS was 50%, with a median OS of 25.6 months, and 3‐year OS of 36%. Thus, we conclude that mogamulizumab monotherapy may improve PFS and OS in some patients with relapsed aggressive ATL, especially those who develop a skin rash as a moderate immune‐related adverse event. Therefore, further investigation is warranted to validate the present observations and to clarify the mechanisms involved in the activity of mogamulizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13343

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 71

Metadata

Authors
Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., Yoshimura, K., Kawamura, K., Takahashi, T., Tobinai, K., & Ueda, R.
Venue
Cancer Science
Publisher
Wiley
Published
2017-08-28
Volume
108
Issue
10
Pages
2022-2029
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2743566600
Cited by
71
References
8
FWCI
4.08
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies. https://app.cochat.ai/papers/10.1111/cas.13343
The paper
Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., Yoshimura, K., Kawamura, K., Takahashi, T., Tobinai, K., & Ueda, R. (2017). Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies. Cancer Science. https://doi.org/10.1111/cas.13343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.